老年晚期转移性结直肠癌患者一线化疗后予以卡培他滨维持治疗对生存时间的延长效果  

Effect of capecitabine maintenance therapy on survival time in elderly patients with advanced metastatic colorectal cancer after first-line chemotherapy

作　　者：闫聿逊 YAN Yu-xun(Oncology Department,Guangrao County Hospital of Traditional Chinese Medicine,Dongying 257300,China)

机构地区：[1]广饶县中医院肿瘤科,257300

出　　处：《中国实用医药》2021年第14期120-122,共3页China Practical Medicine

摘　　要：目的分析老年晚期转移性结直肠癌患者一线化疗后采取卡培他滨维持治疗的效果。方法90例老年晚期转移性结直肠癌患者,通过随机数字表法分为对照组和观察组,每组45例。两组研究对象均接受XELOX一线化疗方案,当靶病灶达到最大缩小率后,对照组停止用药且不接受其他抗肿瘤药物治疗,定期随访观察,试验组患者采取卡培他滨维持治疗。比较两组患者中位无进展生存期(PFS)、治疗效果、不良反应发生情况。结果试验组患者的PFS为(11.58±2.59)个月,明显长于对照组的(8.96±1.47)个月,差异具有统计学意义(t=5.902,P=0.000<0.05)。试验组客观缓解率(RR)为44.44%、疾病控制率(DCR)为82.22%,均高于对照组的35.56%、62.22%,差异具有统计学意义(P<0.05)。化疗期间,对照组不良反应发生率15.56%和试验组的17.78%比较差异无统计学意义(P>0.05)。试验组维持治疗期间不良反应发生率为4.44%(2/45),低于化疗期间的17.78%(8/45),差异具有统计学意义(χ^(2)=4.050,P=0.044<0.05)。结论卡培他滨维持治疗应用于老年晚期转移性结直肠癌患者一线化疗后,能够进一步延长生存时间,提高治疗效果,患者耐受性更好,值得广泛开展。Objective To analyze the effect of capecitabine maintenance therapy on survival time in elderly patients with advanced metastatic colorectal cancer after first-line chemotherapy.Methods A total of 90 elderly patients with advanced metastatic colorectal cancer were divided into control group and observation group according to random numerical table,with 45 cases in each group.Both groups received XELOX first-line chemotherapy.When the target focus reached the maximum reduction rate,the control group stopped the drug and did not accept other anti-tumor drugs,and followed up regularly,while the experimental group was treated with capecitabine maintenance therapy.The progression free survival(PFS),therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results The PFS of the experimental group was(11.58±2.59)months,which was obviously longer than(8.96±1.47)months of the control group,and the difference was statistically significant(t=5.902,P=0.000<0.05).The remission rate(RR)44.44%and disease control rate(DCR)82.22%of the experimental group were higher than 35.56%and 62.22%of the control group,and the difference was statistically significant(P<0.05).During chemotherapy,the incidence of adverse reactions 15.56%of the control group had no statistically significant difference compared with 17.78%of the experimental group(P>0.05).In the experimental group,the incidence of adverse reactions during maintenance therapy was 4.44%(2/45),which was lower than 17.78%(8/45)during chemotherapy,and the difference was statistically significant(χ^(2)=4.050,P=0.044<0.05).Conclusion For elderly patients with advanced metastatic colorectal cancer after first-line chemotherapy,capecitabine maintenance therapy can further prolong the survival time,improve the treatment effect,and the patients are better tolerated.It is worthy of extensive development.

关 键 词：晚期转移性结直肠癌 一线化疗 卡培他滨 维持治疗 老年 

分 类 号：R735.34[医药卫生—肿瘤]